Cabilly patent faring poorly in re-examination

Reuters noted: Genentech Inc. said on Monday [25 Feb 08] the U.S. Patent and Trademark Office [USPTO] has rejected the validity of a key patent that governs the biotechnology company's method of producing some of its drugs. The Cabilly patent involves a method of producing antibodies and antibody fragments, a crucial step in the manufacture of biotechnology drugs.

See also

USPTO gives final rejection in re-exam of Cabilly patent, US 6,331,415